A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Inclusion Criteria:

• Symptomatic EoE;

• For women of childbearing potential, a negative pregnancy test and willing to use ahighly effective method of birth control until end of study;

• Willing and able to adhere to study-related procedures and visit schedule;

• Willing and able to provide informed consent.

Exclusion Criteria:

• Concomitant esophageal disease, relevant GI disease, or any condition, history, orlaboratory abnormality that might interfere with the study;

• Oral or esophageal mucosal infection of any type (bacterial, viral, or fungal);

• Oropharyngeal or dental conditions that prevents normal eating;

• Severe esophageal motility disorders other than EoE;

• Contraindication to or factors that substantially increase risks associated with EGDor biopsy, or narrowing of the esophagus that precludes EGD with a standard 9-10 mmendoscope, stricture requiring dilation within 8 weeks prior to Screening, or theneed for dilation prior to EGD at Baseline;

• Any condition for which the use of corticosteroids is contraindicated (Participantswith well controlled non-insulin dependent diabetes are permitted);

• Active or quiescent systemic fungal, bacterial, viral, or parasitic infections, orocular herpes simplex. Or recent use of IV or oral antibiotics;

• Hypersensitivity, or intolerance to corticosteroids, or to any of the ingredients inthe investigational medicinal product;

• Recent use of disallowed medications, or unwillingness to not use disallowedmedications during the study;

• Recent initiation of a elimination or elemental diet (dietary therapy must remainstable throughout the study);

• Morning serum cortisol level ≤ 5 μg/dL (138 nmol/L);

• Clinically significant abnormal laboratory values;

• Recent or currently planned participation in another interventional trial ;

• Previous participation in this study and had received study treatment;

• Females who are pregnant, breastfeeding, or planning to become pregnant during thestudy;

• Malignancies or history of malignancy within prior 5 years, except for treated orexcised non-metastatic BCC, SCC of the skin, or cervical carcinoma in situ;

• History of alcohol or drug abuse;

• Any other reason, that, in the Investigator's opinion, unfavorably altersparticipant risk, confounds results, or prevents the participant from complying withstudy requirements.